Target product profile and discovery and development path for novel cryptococcal disease treatments

Area of Science:

• Mycology
• Infectious Diseases
• Drug Development

Background:

• Cryptococcus neoformans and Cryptococcus gattii are significant global health threats, particularly impacting individuals with HIV in low- and middle-income countries.
• Current treatments for cryptococcal diseases have limitations, contributing to high morbidity and mortality worldwide.

Purpose of the Study:

• To establish a Target Product Profile (TPP) for novel anti-cryptococcal agents.
• To guide the discovery and development of new treatments addressing unmet needs in cryptococcal disease management.

Main Methods:

• Defined key attributes for new anti-cryptococcal agents based on clinical and microbiological requirements.
• Outlined suggested discovery and development pathways to achieve the TPP.

Main Results:

• The TPP emphasizes improved safety, superior or comparable activity to existing treatments, and broad applicability across patient groups and disease spectrums.
• Key attributes include suitability for all age groups, diverse formulations (oral/intravenous), acceptable regimens, minimal drug interactions, thermostability, and a high barrier to resistance.

Conclusions:

• The developed TPP provides a crucial framework for stakeholders involved in creating next-generation anti-cryptococcal therapies.
• This initiative aims to accelerate the development of more effective treatments to combat cryptococcal meningitis and pneumonia, reducing global disease burden.